UY37906A - Un método para modificar la liberación de un agente terapéuticamente activo de una matriz elastomérica - Google Patents

Un método para modificar la liberación de un agente terapéuticamente activo de una matriz elastomérica

Info

Publication number
UY37906A
UY37906A UY0001037906A UY37906A UY37906A UY 37906 A UY37906 A UY 37906A UY 0001037906 A UY0001037906 A UY 0001037906A UY 37906 A UY37906 A UY 37906A UY 37906 A UY37906 A UY 37906A
Authority
UY
Uruguay
Prior art keywords
active agent
therapeutically active
elastomeric matrix
release
changing
Prior art date
Application number
UY0001037906A
Other languages
English (en)
Inventor
Jyrki Pihlaja
Manja Ahola Dr
Risto Hakala
Piia Hara
Keinänen Antii
Henriikka Korolainen
Original Assignee
Bayer Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Oy filed Critical Bayer Oy
Publication of UY37906A publication Critical patent/UY37906A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0039—Devices retained in the uterus for a prolonged period, e.g. intrauterine devices for contraception
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se provee un método de inmersión para el recubrimiento de un núcleo que comprende una matriz elastomérica y un agente terapéuticamente activo. La inmersión se lleva a cabo como un proceso continuo arrastrando el núcleo por la solución de recubrimiento conteniendo 5-40% en peso de elastómero y 95-60% en peso de solvente, utilizando una velocidad de arrastre adecuada para proporcionar un espesor de recubrimiento de 5-100 µm, y una vez que el núcleo ha pasado por la solución de recubrimiento, se somete a curado, donde el elastómero disuelto en el solvente comprende 20-35% en peso de un agente de relleno.
UY0001037906A 2017-09-27 2018-09-27 Un método para modificar la liberación de un agente terapéuticamente activo de una matriz elastomérica UY37906A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17193367 2017-09-27
EP18167014 2018-04-12

Publications (1)

Publication Number Publication Date
UY37906A true UY37906A (es) 2019-02-28

Family

ID=63592747

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037906A UY37906A (es) 2017-09-27 2018-09-27 Un método para modificar la liberación de un agente terapéuticamente activo de una matriz elastomérica

Country Status (18)

Country Link
US (1) US11666552B2 (es)
EP (1) EP3687495A1 (es)
JP (1) JP7242648B2 (es)
KR (1) KR20200059224A (es)
CN (1) CN111148507B (es)
AU (1) AU2018340266A1 (es)
BR (1) BR112020005928A2 (es)
CA (1) CA3076768A1 (es)
CL (1) CL2020000778A1 (es)
CO (1) CO2020003454A2 (es)
IL (1) IL272878A (es)
JO (1) JOP20200067A1 (es)
MX (1) MX2020007323A (es)
PE (1) PE20211195A1 (es)
SG (1) SG11202001293SA (es)
TW (1) TW201919587A (es)
UY (1) UY37906A (es)
WO (1) WO2019063382A1 (es)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1222897A (zh) * 1996-03-29 1999-07-14 盖里列奥公司 用于形成光学纤维的可剥离聚酰亚胺涂层之方法
US6063395A (en) * 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
US6117442A (en) * 1998-11-12 2000-09-12 Leiras Oy Drug delivery device, especially for the delivery of androgens
AU2002210580A1 (en) * 2000-10-20 2002-04-29 Leiras Oy Drug delivery system
US20020136573A1 (en) * 2001-01-25 2002-09-26 Xerox Corporation Infrared curing of fluoroelastomer coatings formed over silicone rubber in a fuser member
CN1822815B (zh) * 2003-07-10 2012-04-11 沃纳奇尔科特(爱尔兰)有限公司 阴道内药物传递装置
US7914841B2 (en) * 2006-02-09 2011-03-29 Cook Medical Technologies Llc Inline application of coatings
TW200927141A (en) * 2007-11-22 2009-07-01 Bayer Schering Pharma Oy Vaginal delivery system
EP2140860A1 (en) * 2008-07-03 2010-01-06 Bayer Schering Pharma Oy An improved method of contraception
WO2011156648A1 (en) * 2010-06-09 2011-12-15 President And Fellows Of Harvard College Method for producing films
WO2012091680A1 (en) * 2010-12-30 2012-07-05 Nanyang Technological University A device for controlled release of a bioactive agent
KR20120135689A (ko) * 2011-06-07 2012-12-17 (주) 태웅메디칼 약물 방출 스텐트 코팅제의 제조방법 및 이에 의해 제조된 약물 방출 스텐트 코팅제
EP2753303B1 (en) * 2011-09-09 2018-04-04 Axxia Pharmaceuticals, Llc Silicone coated implants
US9434857B2 (en) * 2011-11-15 2016-09-06 Ethicon, Inc. Rapid cure silicone lubricious coatings
AR089765A1 (es) * 2012-01-23 2014-09-17 Bayer Oy Un sistema para el suministro de un farmaco
US20140037964A1 (en) * 2012-08-02 2014-02-06 Haipeng Zheng Optical Article Containing A Self-Healing Coating And Improved Initial Haze
MX2016004930A (es) * 2013-10-18 2016-06-28 Bayer Oy Sistema de administracion intrauterina.
PT3247327T (pt) * 2015-01-21 2019-10-24 Bayer Oy Sistema de entrega de fármaco que compreende um antiinflamatório não esteroide (nsaid) e um composto progestogénico, bem como métodos para produção.
WO2017108676A1 (en) * 2015-12-21 2017-06-29 Bayer Oy Method for manufacturing a drug delivery device and a drug delivery device manufactured according to the method
EP4233999A3 (en) * 2016-12-12 2023-11-22 The Regents of The University of California Implantable and non-invasive stimulators for gastrointestinal therapeutics

Also Published As

Publication number Publication date
CN111148507B (zh) 2023-09-26
CO2020003454A2 (es) 2020-04-13
CL2020000778A1 (es) 2020-09-25
IL272878A (en) 2020-04-30
AU2018340266A1 (en) 2020-03-05
RU2020113426A (ru) 2021-10-27
PE20211195A1 (es) 2021-07-01
WO2019063382A1 (en) 2019-04-04
CA3076768A1 (en) 2019-04-04
JP2020535159A (ja) 2020-12-03
RU2020113426A3 (es) 2022-02-22
US11666552B2 (en) 2023-06-06
BR112020005928A2 (pt) 2020-10-06
MX2020007323A (es) 2020-09-07
CN111148507A (zh) 2020-05-12
JP7242648B2 (ja) 2023-03-20
US20200276159A1 (en) 2020-09-03
TW201919587A (zh) 2019-06-01
JOP20200067A1 (ar) 2020-04-27
KR20200059224A (ko) 2020-05-28
EP3687495A1 (en) 2020-08-05
SG11202001293SA (en) 2020-03-30

Similar Documents

Publication Publication Date Title
CO6801706A2 (es) Método para inhibir o controlar la liberación del agente de tratamiento de pozo
CL2016002996A1 (es) Método para fabricar un material con superficie modificada que comprende: proporcionar un substrato, que comprende un compuesto alcalino salificable o alcalinotérreo; y aplicar una composición de tratamiento líquida que comprende un ácido; material con superficie modificada; y uso del material
CO6940430A2 (es) Nuevos portadores recubiertos para la liberación controlada de agente activo
CL2014000377A1 (es) Sistema y metodo para el tratamiento de una actividad de excavacion que comprende una red de distribucion en comunicación fluida con la actividad de excavacion, un agente espumante y un reactivo suministrados a la red de distribucion; y composicion para dicho tratamiento.
FR3010629B1 (fr) Procede de controle du positionnement de dents
AR094925A1 (es) Aditivos para el control de pérdida de fluido limpio
HN2012001351A (es) Derivados de 3- hidroxi-5-arilisotiazol novedosos
AR096290A1 (es) Un agente de sostén
BR112013028994A2 (pt) método para liberação de conteúdo por meio de uma rede de liberação de conteúdo e rastreador para liberação de conteúdo por meio de uma rede de liberação de conteúdo
BR112018000807A2 (pt) composição, utilização de 40 a 70% em peso de sabão, método para a deposição de um agente de benefícios e processo para a preparação da composição
BR112013020716A2 (pt) precursor de agente quelante, fluido, uso de um precursor de agente quelante e processo para tratar uma formação subterrânea
AR094120A1 (es) Polimero reversiblemente coagulable y redispersable que incluye al menos un monomero que incluye un grupo funcional anfifilo intercambiable y metodos para su utilizacion
BR112013024083A2 (pt) agente de redução do desvio de pulverização, composição pesticida, método para reduzir o desvio de pulverização, composição de pulverização, e, método para produzir uma composição de redução do desvio de pulverização
ECSP16058769A (es) Composicion para la administracion oral de agente bioactivos
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
CL2015002955A1 (es) Proceso para tratar una corriente de colas que comprende agua y sólidos, el proceso comprende: (a) poner en contacto un agente gelificante y un activador con la corriente de colas, (b) atrapar los sólidos dentro de un gel producido a partir del agente gelificante, y (c) depositar el gel en un líquido.
AR090658A1 (es) Terminal para su uso en maquinas punzonadoras y metodo regenerador del terminal
AR097883A1 (es) Tope para un componente tubular recubierto con un depósito metálico compuesto
BR112014003996A2 (pt) polímero, composição e partícula para deposição de um agente de benefício
UY37906A (es) Un método para modificar la liberación de un agente terapéuticamente activo de una matriz elastomérica
CL2012000814A1 (es) Procedimiento de preparacion de un envase que comprende agregar a una solucion de silicona en agua un agente antifungico en una cantidad < 20% p/v formando una solucion homogenea como baño y sumergir laminas de pet previamente extruidas, para posteriormente preparar el envase.
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
BR112016010238A2 (pt) cocristal, métodos para produção de um cocristal e para tratamento de uma semente, composição agroquímica, e, agente de tratamento de semente
BR112013009347A2 (pt) composição, uso de um composto, método para produzir uma camada de liberação adesiva, agente de liberação e película de liberação.
AR106821A1 (es) Composición antimicrobiana

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20231114